

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

OvarianCancer

1st Guidance Development Group (GDG) meeting
on Monday 27- Tuesday 28 April 2009, Board Room, NCCC, Cardiff

ATTENDEES:

| GDG Members | |
|-----------------------------------|-----------------------------------------|
| Mr Sean Duffy (Chair) (SD) | Mr Charles Redman (Lead Clinician) (CR) |
| Dr Sue Barter (SB) | Dr Marcia Hall (MH) |
| Mrs Audrey Bradford (ABr) | Mr Jed Hawe (JH) |
| Dr Laurence Brown (LB) | Mrs Cathy Hughes (CH) |
| Mr Derek Cruickshank (DC) | Mrs Frances Reid (FR) |
| Dr Craig Dobson (CD) | Mr Michael Scanes (MS) |
| Mrs Linda Facey (LF) | Prof Nick Stuart (NS) |
| NCC-C and affiliated staff | |
| Dr John Graham (JG) | Dr Andrew Champion (AC) |
| Angela Bennett (ABe) | Dr Lakshmi Aana (LSA) |
| Dr Karen Francis (KF) | Elise Collins (EC) |
| Angela Melder (AMe) | Eugenia Priedane (EP) |
| Mat Best (MB) | Alec Miners (AMi) |
| NICE staff | |
| Barbara Meredith (BM) | |
| Apologies: | |
| Nicole Elliott (NE) | |

REPORT OF DISCUSSIONS AT THE MEETING

1 Welcome and apologies

SD welcomed everyone to the 1st meeting of the Ovarian Cancer GDG. Apologies were received from Nicole Elliott.

2 Declarations of interest

Interests declared before the 1st GDG meeting:

- SD declared that he was the chief investigator for a trial of a nutritional supplement in patients with ovarian cancer, that is receiving support from Nutricia. This interest was categorised as non-personal pecuniary specific with supervisory responsibility, meaning that SD must withdraw from discussing all topics that include an intervention made by Nutricia. (NOTE: no topics include such an intervention so SD is able to participate in discussion on all topics).
- NS declared that he was chief investigator for a trial investigating the mechanisms of fatigue induced by sunitinib in patients with advanced/metastatic renal cancer, which was receiving funding from Pfizer. This interest was categorised as non-personal pecuniary non-specific meaning that NS can continue to participate in discussion of all guideline topics.
- MS declared that he was a member of the group which recently published the 'Key Messages on Ovarian Cancer'. This interest was categorised as personal non-pecuniary meaning that MS can continue to participate in discussion of all guideline topics.

Minutes of 1st Ovarian Cancer GDG meeting on 27-28 April 2009

- FR declared that in a previous role she was involved in advocating for the role of symptoms in ovarian cancer to be to be acknowledged, based on research emerging from the USA. This interest was categorised as personal non-pecuniary meaning that FR can continue to participate in discussion of all guideline topics.

New interests that were declared at the 1st GDG meeting:

- NS declared that he will be attending the American Society of Clinical Oncology meeting in May 2009 and that Novartis will be reimbursing travelling expenses and subsistence. This reimbursement will not be beyond reasonable amounts. This interest was categorised as personal pecuniary non-specific meaning that NS can participate in discussion of all guideline topics.
- JH declared that he had received a fee from EIDO for writing and reviewing patient information leaflets on cancer topics (but not on ovarian cancer). This interest was categorised as personal pecuniary non-specific meaning the JH can continue to participate in discussion of all guideline topics.

3 Discussion

The GDG were given an introduction to NICE and its guideline development methodology.

A presentation was given on the needs assessment, outlining what data would be collected. The GDG suggested additional data that could be collected.

The GDG discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO question for each topic.

The GDG identified those topics which were potential priorities for economic investigation.

4 Close of meeting

SD thanked members for their input to the meeting, reminded them that the next meeting would be on Tuesday 9 June 2009 starting at 10.45 in the Board Room, NCCC, Cardiff and closed the meeting.